CoChat

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

Open access
Blum, William, Schwind, Sebastian, Tarighat, Somayeh S., Geyer, Susan, Eisfeld, Ann-Kathrin, Whitman, Susan, Walker, Alison, Klisovic, Rebecca, Byrd, John C., Santhanam, Ramasamy, Wang, Hongyan, Curfman, John P., Devine, Steven M., Jacob, Samson, Garr, Celia, Kefauver, Cheryl, Perrotti, Danilo, Chan, Kenneth K., Bloomfield, Clara D., Caligiuri, Michael A., Grever, Michael R., Garzon, Ramiro, Marcucci, Guido · 2012 · Blood
Cited by 135

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

We recently reported promising clinical activity for a 10-day regimen of decitabine in older AML patients; high miR-29b expression associated with clinical response. Subsequent preclinical studies with bortezomib in AML cells have shown drug-induced miR-29b up-regulation, resulting in loss of transcriptional activation for several genes relevant to myeloid leukemogenesis, including DNA methyltransferases and receptor tyrosine kinases. Thus, a phase 1 trial of bortezomib and decitabine was developed. Nineteen poor-risk AML patients (median age 70 years; range, 32-84 years) enrolled. Induction with decitabine (20 mg/m2 intravenously on days 1-10) plus bortezomib (escalated up to the target 1.3 mg/m2 on days 5, 8, 12, and 15) was tolerable, but bortezomib-related neuropathy developed after repetitive cycles. Of previously untreated patients (age ≥ 65 years), 5 of 10 had CR (complete remission, n = 4) or incomplete CR (CRi, n = 1); 7 of 19 overall had CR/CRi. Pharmacodynamic analysis showed FLT3 down-regulation on day 26 of cycle 1 (P = .02). Additional mechanistic studies showed that FLT3 down-regulation was due to bortezomib-induced miR-29b up-regulation; this led to SP1 down-regulation and destruction of the SP1/NF-κB complex that transactivated FLT3. This study demonstrates the feasibility and preliminary clinical activity of decitabine plus bortezomib in AML and identifies FLT3 as a novel pharmacodynamic end point for future trials. This study is registered at http://www.clinicaltrials.gov as NCT00703300.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2012-03-413898

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 135

Metadata

Authors
Blum, W., Schwind, S., Tarighat, S. S., Geyer, S., Eisfeld, A.-K., Whitman, S., Walker, A., Klisovic, R., Byrd, J. C., Santhanam, R., Wang, H., Curfman, J. P., Devine, S. M., Jacob, S., Garr, C., Kefauver, C., Perrotti, D., Chan, K. K., Bloomfield, C. D., Caligiuri, M. A., Grever, M. R., Garzon, R., & Marcucci, G.
Venue
Blood
Published
2012-06-21
Volume
119
Issue
25
Pages
6025-6031
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2057652101
Cited by
135
References
1
FWCI
13.64
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood-2012-03-413898
The paper
Blum, W., Schwind, S., Tarighat, S. S., Geyer, S., Eisfeld, A.-K., Whitman, S., Walker, A., Klisovic, R., Byrd, J. C., Santhanam, R., Wang, H., Curfman, J. P., Devine, S. M., Jacob, S., Garr, C., Kefauver, C., Perrotti, D., Chan, K. K., Bloomfield, C. D., . . . Marcucci, G. (2012). Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. https://doi.org/10.1182/blood-2012-03-413898

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.